8-K: Tonix Pharmaceuticals Announces Full Year 2023 Results and Progress on Fibromyalgia Drug

Tonix Pharmaceuticals reported its full year 2023 financial results and highlighted the progress of its fibromyalgia drug, Tonmya, towards potential FDA approval.

Summary

• Tonix Pharmaceuticals announced its financial results for the fourth quarter and full year ended December 31, 2023.
• The company is focused on seeking FDA approval for Tonmya for the treatment of fibromyalgia, with a pre-NDA meeting scheduled for the second quarter of 2024 and an NDA submission planned for the second half of 2024.
• Positive results from the Phase 3 RESILIENT study in December 2023, along with the first Phase 3 RELIEF study, are expected to support the NDA submission.
• Tonix is also seeking partnerships for its other pipeline programs, leveraging government grants and in-kind contributions to manage R&D expenses.
• The company reported net product revenue of $7.8 million for the full year 2023, primarily from its acquired migraine products, Zembrace SymTouch and Tosymra.
• Net loss for the full year 2023 was $116.7 million, or $6.85 per share, compared to a net loss of $116.9 million, or $20.01 per share, in 2022.
• As of December 31, 2023, Tonix had approximately $24.9 million in cash and cash equivalents, down from $120.2 million at the end of 2022.
• The company completed two registered direct offerings in December 2023 and March 2024, raising approximately $30 million and $4.4 million respectively.
• Tonix has also made progress on other pipeline programs, including TNX-102 SL for acute stress reaction and Long COVID, TNX-1300 for cocaine intoxication, and TNX-1500 for organ transplant rejection.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. There is positive progress on the clinical front, particularly with Tonmya, but the financial situation is concerning with a significant cash burn and net loss. The company is actively raising capital, which is a positive sign of continued operations, but also indicates a need for more funding.

Positives

• The Phase 3 RESILIENT study of Tonmya showed statistically significant and clinically meaningful results in reducing pain, improving sleep quality, reducing fatigue, and improving overall fibromyalgia symptoms.
• Tonix has secured partnerships and collaborations to leverage external resources and manage R&D expenses.
• The company has made significant progress in advancing its pipeline programs, including the initiation of Phase 2 trials for TNX-102 SL and TNX-1300.
• Tonix has received FDA clearance for the IND application for TNX-2900 to treat Prader-Willi syndrome.
• The company has completed the clinical stage of its Phase 1 study of TNX-1500, with topline results expected in the third quarter of 2024.
• Tonix has successfully transitioned to a fully integrated pharmaceutical company, assuming responsibility for the distribution, selling, and marketing of its acquired migraine products.
• The company has secured dual supply sources for the potential launch of Tonmya.
• Tonix has received Rare Pediatric Disease designation from the FDA for TNX-2900 for the treatment of PWS.

Negatives

• Tonix experienced a significant decrease in cash and cash equivalents, from $120.2 million at the end of 2022 to $24.9 million at the end of 2023.
• The company reported a net loss of $116.7 million for the full year 2023.
• Net cash used in operations was approximately $102.0 million for the full year ended December 31, 2023.
• The company's SG&A expenses increased to $34.8 million for the full year 2023, primarily due to sales and marketing expenses associated with the acquired migraine products.
• The company has a history of losses and will need to raise additional capital to fund operations.

Risks

• The company faces risks related to obtaining FDA clearances or approvals for its product candidates.
• There are risks associated with the successful marketing of any of its products.
• The timing and progress of clinical development of product candidates are subject to uncertainties.
• The company has a need for additional financing to continue operations.
• There are uncertainties related to patent protection and litigation.
• The company faces competition from other pharmaceutical companies.
• There are risks associated with government or third-party payor reimbursement.
• The company is dependent on third parties for research and development efforts.

Future Outlook

Tonix is focused on submitting an NDA for Tonmya in the second half of 2024 and is seeking partnerships for its other pipeline programs. The company expects topline results from the Phase 1 study of TNX-1500 in the third quarter of 2024.

Management Comments

• Our near-term focus is seeking U.S. marketing approval for Tonmya for the treatment of fibromyalgia from the U.S. Food and Drug Administration (FDA), said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
• We believe the positive Phase 3 RESILIENT results reported in December of 2023 together with the positive results from the first Phase 3 RELIEF study should satisfy the requirements for approval and, if so, would provide the opportunity for Tonix to launch the first FDA-approved drug for fibromyalgia in more than a decade.
• While Tonix is focusing its resources on progressing Tonmya toward NDA submission and potential FDA approval, we are seeking partnerships and collaborations on our pipeline programs from government agencies, non-profit organizations and other biotechnology or pharmaceuticals companies.

Industry Context

The announcement highlights Tonix's progress in the competitive biopharmaceutical industry, particularly in the development of treatments for fibromyalgia and other central nervous system disorders. The company's focus on partnerships and government grants reflects a common strategy in the industry to manage R&D costs and accelerate development. The potential approval of Tonmya would position Tonix as a key player in the fibromyalgia treatment market.

Comparison to Industry Standards

• Tonix's focus on fibromyalgia treatment aligns with the growing need for effective non-opioid pain management solutions, a trend seen across the pharmaceutical industry.
• The company's approach to leveraging government grants and partnerships for R&D is similar to strategies employed by other biotech companies, such as BioMarin Pharmaceutical and Sarepta Therapeutics, which also rely on external funding and collaborations.
• The reported net loss of $116.7 million is not uncommon for a development-stage biopharmaceutical company, as significant investments are required for clinical trials and regulatory approvals. Companies like Alnylam Pharmaceuticals and Vertex Pharmaceuticals have also experienced substantial losses during their development phases.
• The cash burn rate of $102 million is high, but not unusual for a company with multiple clinical programs. Companies like Moderna and BioNTech have also experienced high cash burn rates during their rapid development phases.
• The company's reliance on registered direct offerings for capital raises is a common practice for biotech companies, similar to how companies like Inovio Pharmaceuticals and Novavax have raised capital.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the progress of its clinical programs.
• Employees are impacted by the company's transition to a fully integrated pharmaceutical company.
• Patients with fibromyalgia may benefit from the potential approval of Tonmya.
• Customers of Zembrace SymTouch and Tosymra will be impacted by the company's assumption of responsibility for distribution, selling, and marketing of these products.
• Suppliers and creditors are impacted by the company's financial performance and its ability to meet its obligations.

Next Steps

• Tonix plans to hold a pre-NDA meeting with the FDA in the second quarter of 2024.
• The company plans to submit an NDA for Tonmya in the second half of 2024.
• Tonix expects to initiate a Phase 2 clinical study of TNX-1300 in the second quarter of 2024.
• The company expects topline results from the Phase 1 study of TNX-1500 in the third quarter of 2024.
• Tonix will continue to seek partnerships and collaborations for its pipeline programs.

Key Dates

Keywords

Tonix Pharmaceuticals, Tonmya, fibromyalgia, NDA, clinical trials, TNX-102 SL, TNX-1300, TNX-1500, Zembrace SymTouch, Tosymra, biopharmaceutical, FDA, R&D, cash, revenue, net loss